Drug intelligence / Profile preview

RGD-404

Development stage: Unknown
Lead developer: RNAGene
Modality: Recombinant Proteins and Enzymes

Overview

RGD-404 is a drug candidate initially developed by RNAGENE, Inc. It is currently in the discovery phase of research and development. Its mechanism of action involves MGMT protein replacements (6-O-methylguanine-DNA methyltransferase replacements). RGD-404 is being investigated for therapeutic use in Nervous System Diseases, Congenital Disorders, and Digestive System Disorders, with a specific active indication for Hepatolenticular Degeneration.

Targets

AGT (O6-methylguanine-DNA methyltransferase)

Beyond the preview

Go deeper on RGD-404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGD-404.

Explore the full profile